| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $355,222 ) |
| | 2024 | 2024 | TEGA THERAPEUTICS INC | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43HL172567 | Testing Novel Advancements to Recombinant Heparin Production | 000 | 1 | NIH | 2/1/2024 | $355,222 |
| | 2024 | 2022 | TEGA THERAPEUTICS INC | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43HL162135 | Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | 001 | 1 | NIH | 9/24/2024 | $0 |
| | 2024 | 2022 | TEGA THERAPEUTICS INC | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43HL162135 | Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | 000 | 1 | NIH | 2/5/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $461,701 ) |
| | 2023 | 2023 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43NS129414 | Title: Development and Validation of Therapy for GM1 Gangliosidosis | 000 | 1 | NIH | 9/13/2023 | $461,701 |
| | 2023 | 2022 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43HL162135 | Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | 000 | 1 | NIH | 2/15/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $321,866 ) |
| | 2022 | 2022 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43HL162135 | Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | 000 | 1 | NIH | 2/4/2022 | $321,866 |
| | 2022 | 2020 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43NS115099 | Title: Intracerebroventricular sulfamidase delivery to the Brain | 000 | 1 | NIH | 11/18/2021 | $0 |
| | 2022 | 2019 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43NS112021 | Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain | 000 | 1 | NIH | 11/2/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $258,169 ) |
| | 2020 | 2020 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43NS115099 | Title: Intracerebroventricular sulfamidase delivery to the Brain | 000 | 1 | NIH | 4/14/2020 | $258,169 |
| | 2020 | 2018 | TEGA THERAPEUTICS, INC. | 3550 GENERAL ATOMICS CT STE G02-102 | SAN DIEGO | CA | 92121-1122 | SAN DIEGO | USA | R43NS108853 | Intracerebroventricular Iduronidase Delivery to the Brain | 000 | 1 | NIH | 12/9/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $225,254 ) |
| | 2019 | 2019 | TEGA THERAPEUTICS INC | 9500 GILMAN DR MC 0713 | LA JOLLA | CA | 92093-5004 | SAN DIEGO | USA | R43NS112021 | Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain | 000 | 1 | NIH | 7/31/2019 | $225,254 |
|
| Issue Date FY: 2018 ( Subtotal = $225,000 ) |
| | 2018 | 2018 | TEGA THERAPEUTICS INC | 9500 GILMAN DR MC 0713 | LA JOLLA | CA | 92093-5004 | SAN DIEGO | USA | R43NS108853 | Intracerebroventricular Iduronidase Delivery to the Brain | 000 | 1 | NIH | 7/20/2018 | $225,000 |
| | 2018 | 2015 | TEGA THERAPEUTICS INC | 9500 GILMAN DR MC 0713 | LA JOLLA | CA | 92093-5004 | SAN DIEGO | USA | R43NS089383 | Intranasal Sulfamidase Delivery to the Brain | 000 | 1 | NIH | 12/28/2017 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $237,138 ) |
| | 2015 | 2015 | TEGA THERAPEUTICS INC | 7330 CARROLL RD STE 200 | SAN DIEGO | CA | 92131 | SAN DIEGO | USA | R43NS089383 | Intranasal Sulfamidase Delivery to the Brain | 000 | 1 | NIH | 9/14/2015 | $237,138 |
|
|
